

MEDIA INFORMATION 2022

www.international-pharma.com



OUR BRAND

Supporting the Industry Through Communication

Peer reviewed by our carefully selected editorial advisory panel and extensive research network IPI, celebrating its 15th year, provides a proven supportive means of communication to the pharmaceutical. bio-pharmaceutical, and medical devices industry including the latest in research and innovations, drug discovery and development, regulatory guidelines, manufacturing and packaging, supply chain management, marketing and communication strategies and so much more which will enable them to be more efficient, bring products to market faster, reduce cost and make healthcare accessible to all.




Our Focus

Our authors – who share their knowledge and offer practical experiences with our readers - are executives, managers, and investigators who are involved in the best practice in outsourcing managment for the pharmaceutical and biopharmaceutical industries.

Our Readers

With a global audience of 38,529* engaged pharmaceutical, bio-pharmaceutical and medical device professionals, IPI connects you to the industry executives who are most receptive to your marketing message.







OUR EXPERTS



LUCY Robertshaw

Lucy Robertshaw is the Editor and member of the Editorial Advisory Board for IPI - International Pharmaceutical Industry Journal. Lucy has many years of experience of working with AstraZeneca, Lucy is a member of the American Women's Club in Stockholm, where she loves to meet likeminded people and to enjoy her passion for networking. Through this networking Lucy provides insights and interviews from regulatory authorities, pharmaceutical companies, and vendors, reporting from conferences and events, and analysing the current pharmaceutical industry.



Tassilo Korab

Tassilo Korab is the packaging industry correspondent of IPI. Tassilo has been in the packaging industry for more than 20 years. As a recognised expert in flexible packaging, he holds an MSc in Healthcare Economics, as well as having written several publications on patient compliance. standards and regulations for child resistant packaging and the war against counterfeits. Tassilo is Managing Director of TKM Handels GmbH, a consulting company in the sector of flexible packaging for the pharmaceutical and healthcare industries. He was one of the co-founders of HCPC Europe. Tassilo guides the IPI Journal with his indepth knowledge of the Pharma Packaging Industry.





Dr. J. Rick Turner

Dr J. Rick Turner is the US correspondent of IPI -International Pharmaceutical Industry Journal. He is an experimental research scientist and clinical trialist, with particular interests in the cardiac and cardiovascular safety of noncardiovascular drugs and the development and use of drugs for hypertension and type 2 diabetes mellitus. Dr Turner was Chairman of the Department of Clinical Research at Campbell University School of Pharmacy, a Clinical Submissions Scientist at GlaxoSmithKline, and President & Chief Scientific Officer at Turner Medical Communications LLC. He has published a total of 14 authored and edited books, and 130 peer-reviewed papers and articles in professional journals. He is a member of various professional societies, a Fellow of the Society of Behavioral Medicine, and a Senior Fellow at the Center for Medicine in the Public Interest. With his wide knowledge of the pharmaceutical drug discovery industry and his exceptional writing skills, Dr Turner advises and contributes thought leadership articles within IPI.

IPI Editorial Advisory Board

Our Editorial Advisory Board ensures the credibility and accuracy of our content through their expertise. The Board members come from all walks of the industry - Regulatory agencies, Ministry of Health, Pharmaceutical & Bio-Pharmaceutical Companies, and all other stakeholders. They have experience with Drug Discovery & Development, Delivery technology, Clinical Research, Contract Manufacturing, Packaging, Supply Chain Management, and other fields. These international experts offer their mastery to review manuscripts, suggest topics and advise editors on industry issues. Through their contributions, our readers benefit by receiving credible, practical and relevant articles and commentaries.






CIRCULATION & READERSHIP

In Print

International Pharmaceutical Industry (IPI) is a globally distributed publication with a presence across the world. Since 2008, IPI is distributed in conjunction with the IFMPA Database of all their member Companies and Organisations globally. Each quarterly issue has a print copy distribution figure of 25,000 copies, providing strong access to the International Market. IPI is sent directly to key decision makers in the Pharmaceutical Industry, addressing all stakeholders.


READERSHIP BY JOB FUNCTION				
11%	Heads of Operations			
11%	Heads of Packaging Management			
11%	Heads of Research & Development			
9%	CEO / CFO /CMO			
9%	Heads of Procurement			
8%	Heads of Formulation Development			
8%	Heads of Production			
8%	Heads of Business Development			
7%	Heads of Clinical Trials			
7%	Medical Directors			
6%	Logistics & Supply Chain Managers			
5%	Heads of Regulatory Affairs			
CIRCULATION				
Print Subscribers		25,000		
Digital Subscribers 18,202				
DIRECT MAIL				
IPI E-Newsletters		18,202		
E-Blast 17,202				



In Digital

IPI E-Newsletter – provides the latest business news, product news, events, technical papers, and links to company information and services. This gives you the latest update on products and services offered to the global pharmaceutical industry.

IPI E-Newsletter & IPI E-Blast is sent to more than 18,202 professionals working for the leading biopharmaceutical and pharmaceutical companies, contract manufacturing & packaging companies, clinical research organisations, other vendors & service providers, and government & non-government agencies.







RATES & DATA

Print Media

PRINT ADVERTISEMENT			
Double Page	£ 5,250		
Full Page	£ 2,850		
Half Page (Vertical / Horizontal)	£ 1,650		
Prime Positions:			
Inside Front Cover	£ 5,950		
Inside Back Cover	£ 4,850		
Outside Back Cover	£ 7,250		
Page Opposite Contents	£ 3,750		
Page Opposite Editor's Letter	£ 3,750		
1 Page Corporate Profile	£ 2,000		
Front Cover LOGO	£ 1,500		

Discounts apply for series bookings.

Inserts, reprints and recruitment advertisers' rates are available on application.

For more information contact: info@ipimedia.com

MECHANICAL SPECIFICATIONS

(In mm, Height x Width, with Type, Trim, Bleed)

	Туре	Trim	Bleed
Full Page:	261 x 181	297 x 210	303 x 216
½ Pages (horizontal)	135 x 186	148 x 210	154 x 216
½ Pages (vertical)	273 x 92	297 x 105	303 x 108

Please supply digitally, ideally a press ready PDF.

Alternatively supply as a flat image file (Tiff, Jpeg, EPS, PSD etc) ensuring that all fonts are embedded, images are Highresolution and the file is CMYK.

Digital Media

WEBSITE ADVERTISEMENT				
Home Page Pop-up 640 x 480 px	£2,500 for 3 mos			
Corner Peel (Specs sent upon request)	£1,800 for 3 mos			
Leader Board 728 x 90 px	£1,200 for 3 mos			
Rectangular (right/left column) 300 x 250 px	£1,000 per 3 mos			
Skyscraper (right/left column) 300 x 600 px	£1,000 per 3 mos			
Host Videos	£1,000 for 3 mos			
Sponsored Articles	£1,000 per 3 mos			
Events Listing	£250 for 3 mos			
News	£200 for News			

E-Blast & E-Newsletter Campaign

IPI holds a secured database of over 18,202 professionals working for the leading pharmaceutical, midsized biotechnology companies, CRO's, Contract Manufacturers, Packagers and other stakeholders, who have given their consent to receive a Weekly Electronic Newsletter and any 3rd party relevant supplier information. IPI provides a direct communication link to these high net worth individuals through its Electronic Campaign Platforms.

E-Newsletter	£250 Per Week (Minimum of 4 weeks booking)
E-Blast: HTML E-Blast	£1,645 Per Campaign







Cost: £2.500

CONTENT PROGRAMS

Dedicated Dialogue

IPI will conduct an interview with an expert from your company (executive, corporate manager etc). This interview will be marketed through the following channels: Featured as a 2 Page Interview in IPI, the interview will be hosted on the www. ipimediaworld.com website, and will also be promoted through the IPI E-Newsletter. We will give you a designed PDF of the interview which you can either host on your website, or share on your social media platforms.

✓ **Content Tactic:** Branding/Awareness, Thought Leadership



Cost: £7.850

Sponsored eBook

A sponsored custom eBook or eBook series on topic(s) of your choice or a collaborative topic in conjunction with IPI editorial team. This program is designed to deliver high quality leads.

Content Tactic: Branding/Awareness, Lead Generation, Thought Leadership



Cost: £2,000 + travel

Talking Point

A member of the IPI team will attend your company's conference presentation and conduct an in-person interview with your presenter. The Q & A will be published as a 2-3-page interview in a print & digital issue of IPI, and shared through our E-Newsletter, and social media channels.

✓ **Content Tactic:** Branding/Awareness, Thought Leadership







DIGITAL OFFERINGS

Online Website Advertising

Display your ad in front of decision makers in the field by placing your banner advertisement on: international-pharma.com

✓ Content Tactic: Branding/Awareness, Web Traffic



Ad Retargeting

Once a visitor leaves international-pharma.com, your display ad will follow them across the web, driving targeted groups to your website to learn more about your products or services.

Content Tactic: Branding/Awareness, Web Traffic



Corporate Profile Listing

Exclusive resource section on the International Pharmaceutical Industry (international-pharma.com) website where your company can disseminate collateral, videos, 900 word company descriptions, USP to drive website traffic, generate leads and more. Your content block is not an ad unit and does not go into rotation so it is visible 24/7.

✓ **Content Tactic:** Branding/Awareness, Web Traffic



wered by IMAS knowledge of the sector, designed with unique Italian style, built to deliver top-level performance, IP tive's tablet presses are the best solution to handle all production volumes. With over 5,000 installations worldwide, tive's is a world leader in capsule filling. High accuracy control and unrivalled experience in high containment are the Umarks of IMA Active's filling solutions.

ne technology, intelligent design, enduring reliability. IMA granulation and ting technologies make processing lean and highly efficient.

MA Active supplies a complete range of granulation equipment: from small the aboratory scale equipment for R&D purposes to industrial equipment for R&D purposes to industrial equipment for R&D purposes to industrial equipment for R&D purposed to industrial equipment for R&D purposed to the proof-special equipment for proof-special equip

IMA Active's handling systems include a wide range of equipment and technical solutions: dispensing and feeding systems, bins and drums, tumblers, lifting colu-and high containment valves. Flexibility is the hallmark of IMA Active's washing stations: smart solutions for enhancing efficiency while minimizing water and detergent consumption.

nstallations worldwide for dispensing, handling, granulating, illing and coating of category IV and V products, IMA Active is able nge of solutions to work with HAPI (Highly Active Pharmaceutical el approach to solid dose contained production IMA Arriva Jahvesi tableting, capsule filling and coating of category IV and V products to supply a wide range of solutions to work with HAPI (Highly Act Ingredients), 4 global approach to solid doos contained productior for the development and set-up of products and process solutions









DIGITAL OFFERINGS

BOOST - Custom Targeted Email Campaign

BOOST is a highly targeted, data driven, HTML E-Campaign tool. BOOST contains over 100,000 decision makers from global companies involved in the pharmaceutical and scientific industries served by our leading publications.

Content Tactic: Web Traffic, Lead Generation

MYODERM STRATEGIC. STREAMLINED. SMARTER. ARE YOU USING THE BEST SOURCING, LABELING AND DISTRIBUTION FOR YOUR TRIAL? Any company can deliver clinical supplies to your study sites. But how many can... · Reduce or eliminate drug waste? · Provide flexible sourcing, labeling, and distribution? · Source from manufacturers and distributors down to the local level in more than 60 countries? · Offer faster and more cost-effective labeling services? · Actively adapt your sourcing strategy to keep your trial running at peak When it comes to delivering open label drugs to clinical study sites, no one matches Myoderm for flexibility, buying power and expert market knowledge. We are The Clinical Trial Supply Company. CASE STUDY: SEE FOR YOURSELF Oncology clinical trial supply is becoming increasingly more complex. An already demanding trial that required high-level logistical knowledge and had a product restriction per patient per site became more challenging when the manufacturer issued a product recall. Myoderm's experience and sourcing relationships led to a solution that resulted in waste reduction and cost savings for the client. DOWNLOAD NOW CONTACT US Ready to learn more or have questions on how Myoderm can support your next clinical trial? Contact us for more information. © 2019 Myoderm

IPI -**E-Newsletter**

IPI - E-Newsletter is published weekly to over 18,202 highly engaged pharmaceutical and bio-pharmaceutical professionals. Each edition features a premium collection of news, blogs, advertising banners, events, webcasts and more.

IPI Newsletter also contains highlighted articles from the most current edition of the journal.

✓ Content Tactic: Branding/Awareness, Web Traffic





DIGITAL MEDIA INFORMATION

international-pharma.com

Average E-Blast CTR: 3.1 Average E-Newsletter CTR: 3.9

international-pharma.com is an online portal providing readers with peer reviewed articles from industry experts, news bulletins, a company directory and technical white papers. Website visitors are also able to access the entire archive of IPI articles.

The location report from Google analytics (2020/2021) reveals that over 88% of visits came from Europe, America, Asia and Middle East. The leading countries are United States, United Kingdom, Germany, France, Norway, Switzerland, Italy, China, India, UAE, Saudi Arabia and Australia.

Social Media

www.twitter.com/international-pharma





Total amount of Impressions in 2021:

21,402,719

Total amount of clicks in 2021:

68,513

Total amount of unique Impressions in 2021:

17,742,537

Total amount of unique clicks in 2021:

58,418

White Papers

international-pharma.com presents technical white papers, highlighting each contributing organi-sation's expertise and knowledge within its fields. White papers appear on the site in an accessible, searchable archive, which can be easily viewed and downloaded by readers.

Digital Journal & eNewsletter

The digital magazine edition of IPI is a fully interactive, page turning version of the print magazine. The e-Journal is emailed to a growing list of digital subscribers in a regular newsletter, expanding IPI's print circulation to a broad international readership.

Company Capabilities

international-pharma.com's online company profile listings provides a guide for readers wishing to find out more about service providers. The company listings features company contact information, along with an 800 word description, company logo and website links.





IPI provides the pharmaceutical & biopharmaceutical industry with comprehensive coverage of key scientific, technology, regulatory and business topics.

International Pharmaceutical Industry is a peer reviewed journal. We are committed to editorial integrity. Supported by an elite group of reviewers and industry experts, IPI brings you contemporary and authoritative articles which will guide the industry in the best practice in regulatory issues, market analysis, drug discovery, development, delivery methods, clinical research, laboratories, analytical testing, custom and contract manufacturing, primary and secondary packaging, logistics and supply chain management.

Peer Review Protocol

Criteria for Publication

Provides strong evidence for its conclusions. • Novel • Unbiased • Non Promotional. Of extreme importance to stakeholders in the Pharmaceutical and Biopharmaceutical Industry. In general, to be acceptable, a paper should represent an advance in understanding likely to influence thinking in the field. There should be a good and clear reason why the work deserves the visibility of publication in a Pharma Publications journal rather than in a different journal.

Author Guidelines

A typical article will be about 2000–2500 words. You can include from 4-5 images, graphs or graphics with the article.

The article must be sent to us in a Word Document format, and all associate images should be supplied separately in a High Resolution (PDF, Jpeg, PNG) file, 300 dpi min.

Editorial Sections

include but are not limited to:

Regulatory & Market

Finished Dose Formulation

Clinical & Medical Research

Custom & Contract Manufacturing

API & Chemicals

Laboratories

Information Technology

Patient Adherence Management

Drug Discovery & Development

Drug Delivery Technologies

Analytical & Biochemical Laboratories

Packaging

Logistics & Supply Chain

Innovations

Investment & Finance

Serialisation & Brand Protection

Article Title: Should not be more than 10 words in length. **Author Bios:** Author Bios should not be more than 60 words in length. Please also supply us with Author Email.

Author Picture(s): Please send Author(s) Headshots in High Resolution (300dpi min), (Jpeg, PDF format)

Please visit our website international-pharma.com, or request from our editorial team the entire Peer Review Protocol, and the Author Guidelines.





March

Volume 14 Issue 1

Issue Date:

15th March 2022

Editorial Submission Deadline: 15th J

15th January 2022

Regulatory & Market

- Mitigating the impact of the new EU Medical Device Regulations
- Key issues and industry positions on the US FDA draft guidance for MDIs and DPIs
- Security by Design: taking action to reduce the risks
- Navigating your way through contradicting regulations
- Insights into the global licensing trends: The expanding role of Pharmacovigilance in product development

Drug Discovery, Development & Delivery

- The challenge of improving R&D productivity
- The importance of excipients in generic product development
- The increasing focus on microbiome research
- Transdermal drug delivery
- Nutraceuticals & medicated confectionaries

Clinical & Medical Research

- From bench to bedside: The importance of protocol design and holistic trial management
- Immuno-oncology innovations transforming cancer treatment
- Incorporating digital health in clinical operations executions
- Patient centricity in study design and implementation
- Study oversight models and quality / risk management systems
- ePRO, eCTD, eCOA The future of M Health Trials

Manufacturing

- APIs and excipients
- · Lyophilisation and Freeze Drying
- Process control and automation
- Clean room technology
- Bioprocessing: single-use systems and disposable devices
- · Vial and cartridge fill-finish equipment
- New manufacturing technology platforms for Biosimilars

Packaging

- Robotics and automation instruments for packaging
- The rise of single-use systems
- Coding and marking technologies for primary packaging
- Tackling patient adherence challenges
- · Child resistant and senior friendly packaging

Technology

- Big Data and Al initiatives changing the competitive landscape
- The 'beyond the pill' model: apps and wearable devices
- The electronic laboratory notebooks: addressing data security and privacy concerns
- Using advanced analytics and language processing capabilities to deliver clinical decision support

- Serialisation: data integrity and control
- Achieving traceability and transparency across the entire supply chain
- IoT solutions





June

Issue Date: 15th June 2022

Volume 14 Issue 2

Editorial Submission Deadline: 15th April 2022

Regulatory & Market

- Standards, Regulatory Landscape and Compliance
- The new requirements for post-market surveillance reporting
- Mergers and acquisitions: how technology is changing the game
- Regulatory initiatives fostering demand for pharmacogenomics technology
- The business case for the identification of medicinal products (IDMP) implementation
- Marketing authorisation, regulatory requirements and strategies

Drug Discovery, Development & Delivery

- Phenotypic screening the renaissance of phenotypic drug discovery
- Optimising bioavailability using particle engineering, improving drug safety and ADME, and genomics
- Oral drug delivery
- Nutraceuticals
- · Coating technology

Clinical & Medical Research

- Patient centricity in support of clinical operations and study adherence
- Advanced formulations and processing technology in oral delivery of drugs
- The importance of Subject Recruitment and Retention to clinical trial success
- Unique challenges and opportunities in orphan diseases
- Outsourcing and collaborative research in clinical trials

Manufacturing

- Advances in manufacturing and processing impacting formulation development
- The modified release technology in the development of NCEs
- FDC shaping innovation in formulation development
- Robotics in aseptic drug manufacturing: Single-unit dosage forms
- · Lyophilisation & Freeze drying

Packaging

- Films & flexible packaging
- Compliance packaging the patient centric packaging
- Combating counterfeiting printed electronics for smart packaging
- Primary packaging for parenterals
- Plastic injection moulding

Technology

- Sensors and digital services for personalised care
- The 'chip-on-a-pill' technology
- The potential of machine learning and AI
- Drug development software & technology
- Wearable sensor technology

- Building a patient-centric supply chain
- Supply chain meets blockchain innovation
- Temperature control innovative solutions
- GDP requirements & compliance





September

Issue Date:

15th September 2022

Volume 14 Issue 3

Editorial Submission Deadline: 15th July 2022

Regulatory & Market

- Understanding the overlap of MDR with IVD, Clinical Trial Regulation (CTR) for human use.
- Falsified Medicines Act and Identification of Medicinal Product (IDMP)
- Aligning IP strategy with business strategy
- Consolidation and competition in the pharmaceutical industry
- The market dynamics driving trends in M&A

Drug Discovery, Development & Delivery

- The rise of non-animal technologies in safety assessment
- Nano-medicine targeted drug delivery
- Targeting RNA with small molecules recent advances based on novel scientific insights
- Current methods of rational drug design
- Competitive edge: Target Identification/Target Validation
- Use of next-generation sequencing in-vitro diagnostics
- Opportunities for biologics delivery
- Respiratory drug development & delivery

Clinical & Medical Research

- Application challenges of the new EU Clinical Trial Regulation
- Future perspectives and innovations in clinical studies
- High-throughput screening, databases and proprietary algorithms
- FDA' Post-marketing safety surveillance program for drug and therapeutic biologic products

Manufacturing

- The future of dosage forms
- Advances in liquid-based formulation technologies
- The liquid fill approach to solid oral formulations
- Advanced aseptic processing technology
- Risk-based isolation and barrier technology Barrier isolution
- · PAT Quality by Design
- Environmental protection & facility management

Packaging

- Digital mass serialisation
- Translation & Licence regulation
- Glass packaging
- · Active & Passive temperature control packaging
- Sterile packaging

Technology

- The rise of virtual drug design tools
- · Virtual screening and database building
- Scientific apps in the labs
- The 3D printed pill technology

- New approaches in pharma logistics
- Temperature control logistics
- Time / Temperature monitoring
- · Optimisation and cost management





December

Issue Date:

15th December 2022

Volume 14 Issue 4

Editorial Submission Deadline: 15th October 2022

Regulatory & Market

- The new EU Medical Device Regulations
- Ensuring a strategic balance between compliance risk and value
- Big Data's role in compliance: applying advanced data analytics techniques to identify and quantify new and emerging risks
- The next generation transparency reporting and expert engagement
- Cybersecurity vulnerabilities in medical devices: taking actions to reduce the risks

Drug Discovery, Development & Delivery

- Advancements of gene editing technologies (CRISPR/CAS9)
- Immuno-oncology (CAR-T cells)
- The state of antibiotic drug discovery recent breakthroughs – the discovery of Teixobactin and its analogs
- The potential of AI-based tools in drug discovery and development
- The importance of stability and bioavailability in early-phase formulations
- Real-world challenges for inhaled medicines
- Respiratory drug development & delivery
- Meter Dosage Inhalers (MDI) / Dry Powder Inhalers (DPI) & Breath Actuated Inhalers (BAI)

Clinical & Medical Research

- Guiding the clinical trials industry in digital health
- Strategic alignment of study objectives and endpoints to drive value and fill data gaps
- The increasing inclusion of biomarkers as an eligible criterion for participation in clinical trials
- Assessing complexity of study design and matching to systems based on efficiency and costeffectiveness

Manufacturing

- Small molecule API process development
- Process development and new technologies for downstream manufacturing
- New cell culture techniques
- Prefilled syringe fill-finish equipment
- HPAPIs: innovative containment strategies ensuring high-potency handling requirements
- Customised pharmaceutical technologies: Singleunit dosage forms (effervescent tablets, Blow-fillseal vials)
- Clean room technology

Packaging

- Robotics and automation instruments for packaging
- The serialisation deadline: headache or opportunity?
- Glass packaging
- Coding and marking technologies for primary packaging
- Tackling patient adherence challenges

Technology

- Big Data and AI initiatives changing the competitive landscape
- The 'beyond the pill' model: apps and wearable devices
- The electronic laboratory notebooks: addressing data security and privacy concerns
- Using advanced analytics and language processing capabilities to deliver clinical decision support

- The security of patient data in digital supply chains
- European Falsified Medicine Directive
- RFID and NFC Tags





ADDITIONAL PRODUCT

Outsourcing & Innovations Supplement 2022

Issue Date: October 2022

Innovations are in the forefront within the Pharmaceutical Outsourcing Industry. New cutting edge methods, technology and process are driving this sector. Companies need a platform to detail these inventive models to prospective client. In line with this IPI creates a Yearly Innovations Supplement, to draw attention to companies latest innovations, and their future growth potentials, enabling service users to make strategic decisions on their future service providers. With 10,000 copies, produced in November of every year, the supplement is distributed at a number of the industry's best events in the following 12 months, giving clients assured high visibility.

Each Company receives 2 pages:

- Left Hand Page (600 650 words Company Profile + Logo and 2 Pictures)
- Right Hand Page A4 Advert
- Each Company will feature their LOGO on the Index Page, and 5 Company Key Features

RATES		
Outside Back Cover + 2 Page Profile	£3,000	
Inside Front Cover Advert + 2 Page Profile	£2,500	
Inside Back Cover + 2 Page Profile	£2,200	
1 Page Profile + 1 Page Advert	£1,500	
2 Page Company Profile	£1,500	









